Miroslav Kosar, Leonard Mach, Erick M Carreira, Marc Nazaré, Pal Pacher, Uwe Grether
{"title":"大麻素受体 2 型（CB2R）调节剂专利回顾（2016 年至今）。","authors":"Miroslav Kosar, Leonard Mach, Erick M Carreira, Marc Nazaré, Pal Pacher, Uwe Grether","doi":"10.1080/13543776.2024.2368745","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Cannabinoid receptor type 2 (CB<sub>2</sub>R), predominantly expressed in immune tissues, is believed to play a crucial role within the body's protective mechanisms. Its modulation holds immense therapeutic promise for addressing a wide spectrum of dysbiotic conditions, including cardiovascular, gastrointestinal, liver, kidney, neurodegenerative, psychiatric, bone, skin, and autoimmune diseases, as well as lung disorders, cancer, and pain management.</p><p><strong>Areas covered: </strong>This review is an account of patents from 2016 up to 2023 which describes novel CB<sub>2</sub>R ligands, therapeutic applications, synthesis, as well as formulations of CB<sub>2</sub>R modulators.</p><p><strong>Expert opinion: </strong>The patents cover a vast, structurally diverse chemical space. The focus of CB<sub>2</sub>R ligand development has shifted from unselective dual-cannabinoid receptor type 1 (CB<sub>1</sub>R) and 2 agonists toward agonists with high selectivity over CB<sub>1</sub>R, particularly for indications associated with inflammation and tissue injury. Currently, there are at least eight CB<sub>2</sub>R agonists and one antagonist in active clinical development. A better understanding of the endocannabinoid system (ECS) and in particular of CB<sub>2</sub>R pharmacology is required to unlock the receptor's full therapeutic potential.</p>","PeriodicalId":12314,"journal":{"name":"Expert Opinion on Therapeutic Patents","volume":" ","pages":"665-700"},"PeriodicalIF":5.4000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Patent review of cannabinoid receptor type 2 (CB<sub>2</sub>R) modulators (2016-present).\",\"authors\":\"Miroslav Kosar, Leonard Mach, Erick M Carreira, Marc Nazaré, Pal Pacher, Uwe Grether\",\"doi\":\"10.1080/13543776.2024.2368745\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Cannabinoid receptor type 2 (CB<sub>2</sub>R), predominantly expressed in immune tissues, is believed to play a crucial role within the body's protective mechanisms. Its modulation holds immense therapeutic promise for addressing a wide spectrum of dysbiotic conditions, including cardiovascular, gastrointestinal, liver, kidney, neurodegenerative, psychiatric, bone, skin, and autoimmune diseases, as well as lung disorders, cancer, and pain management.</p><p><strong>Areas covered: </strong>This review is an account of patents from 2016 up to 2023 which describes novel CB<sub>2</sub>R ligands, therapeutic applications, synthesis, as well as formulations of CB<sub>2</sub>R modulators.</p><p><strong>Expert opinion: </strong>The patents cover a vast, structurally diverse chemical space. The focus of CB<sub>2</sub>R ligand development has shifted from unselective dual-cannabinoid receptor type 1 (CB<sub>1</sub>R) and 2 agonists toward agonists with high selectivity over CB<sub>1</sub>R, particularly for indications associated with inflammation and tissue injury. Currently, there are at least eight CB<sub>2</sub>R agonists and one antagonist in active clinical development. A better understanding of the endocannabinoid system (ECS) and in particular of CB<sub>2</sub>R pharmacology is required to unlock the receptor's full therapeutic potential.</p>\",\"PeriodicalId\":12314,\"journal\":{\"name\":\"Expert Opinion on Therapeutic Patents\",\"volume\":\" \",\"pages\":\"665-700\"},\"PeriodicalIF\":5.4000,\"publicationDate\":\"2024-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Expert Opinion on Therapeutic Patents\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/13543776.2024.2368745\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/7/2 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Therapeutic Patents","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13543776.2024.2368745","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/2 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
Patent review of cannabinoid receptor type 2 (CB2R) modulators (2016-present).
Introduction: Cannabinoid receptor type 2 (CB2R), predominantly expressed in immune tissues, is believed to play a crucial role within the body's protective mechanisms. Its modulation holds immense therapeutic promise for addressing a wide spectrum of dysbiotic conditions, including cardiovascular, gastrointestinal, liver, kidney, neurodegenerative, psychiatric, bone, skin, and autoimmune diseases, as well as lung disorders, cancer, and pain management.
Areas covered: This review is an account of patents from 2016 up to 2023 which describes novel CB2R ligands, therapeutic applications, synthesis, as well as formulations of CB2R modulators.
Expert opinion: The patents cover a vast, structurally diverse chemical space. The focus of CB2R ligand development has shifted from unselective dual-cannabinoid receptor type 1 (CB1R) and 2 agonists toward agonists with high selectivity over CB1R, particularly for indications associated with inflammation and tissue injury. Currently, there are at least eight CB2R agonists and one antagonist in active clinical development. A better understanding of the endocannabinoid system (ECS) and in particular of CB2R pharmacology is required to unlock the receptor's full therapeutic potential.
期刊介绍：
Expert Opinion on Therapeutic Patents (ISSN 1354-3776 [print], 1744-7674 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles on recent pharmaceutical patent claims, providing expert opinion the scope for future development, in the context of the scientific literature.
The Editors welcome:
Reviews covering recent patent claims on compounds or applications with therapeutic potential, including biotherapeutics and small-molecule agents with specific molecular targets; and patenting trends in a particular therapeutic area
Patent Evaluations examining the aims and chemical and biological claims of individual patents
Perspectives on issues relating to intellectual property
The audience consists of scientists, managers and decision-makers in the pharmaceutical industry and others closely involved in R&D
Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
